Compare research programmes
Compare factual records. Programmes can target different organs and diseases, so the table does not rank their clinical value.
| Record | ER-100 | Rentosertib |
|---|---|---|
| Organisation | Life Biosciences | Insilico Medicine |
| Field | Cellular reprogramming | AI and biological discovery |
| Development record | Human study | Published human results |
| Evidence includes | Cells, Animals, Humans | Cells, Animals, Humans |
| AI’s recorded role | No programme-specific AI contribution verified | PandaOmics helped prioritise TNIK as a fibrosis target; Chemistry42 generated candidate inhibitors that researchers synthesised and tested. |
| Research question | ER-100 is an OSK partial-reprogramming gene therapy in an open-label Phase 1 eye study. Its developer reports 56-day safety observations in three glaucoma patients and exploratory visual-field changes in two. | Rentosertib connects AI-assisted target selection and molecular design with published lung-disease trial results. A September 2026 analysis examined ageing clocks in stored samples. The developer also announced first dosing in a larger Phase 3 study; the medicine remains experimental. |
| Next assessment | Further dose escalation, longer safety observation and a subsequent controlled study will determine whether early functional observations replicate. The interim company presentation is not proof of human rejuvenation. | GENESIS-IPF-3 is the next major clinical test. Its registered endpoints and subsequent results will address lung disease. A broader ageing hypothesis needs experiments that can distinguish disease improvement from effects on ageing in other tissues. |
| Sources | 7 identified sources | 4 identified sources |
Different populations, endpoints and delivery methods can make direct comparisons inappropriate. Read each programme’s study record before interpreting a difference.